Evaluation of liver fibrosis in chronic hepatitis B patients with 2D shear wave elastography with propagation map guidance: a single-centre study

• Published in: BMC medical imaging Vol. 22; no. 1; p. 50
• Main Authors: Kavak, Seyhmus, Kaya, Safak, Senol, Ayhan, Sogutcu, Nilgun
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 18.03.2022; BioMed Central; BMC
• Subjects: Antiviral agents; Antiviral Agents - therapeutic use; Aspartate; Chronic hepatitis B; Elasticity Imaging Techniques - methods; Fibrosis; Hepatitis B; Hepatitis B, Chronic - complications; Hepatitis B, Chronic - diagnostic imaging; Hepatitis B, Chronic - drug therapy; Humans; Liver; Liver - diagnostic imaging; Liver - pathology; Liver Cirrhosis - diagnostic imaging; Liver Cirrhosis - pathology; Liver fibrosis; Propagation map; Prospective Studies; Rankings; Shear wave elastography; Wave propagation; Shear wave elastography; Liver fibrosis; Chronic hepatitis B; Propagation map
• ISSN: 1471-2342; 1471-2342
• DOI: 10.1186/s12880-022-00777-7

The aims of this study were to evaluate liver fibrosis with two-dimensional (2D) shear wave elastography (SWE) in patients with chronic hepatitis B (CHB), to compare 2D-SWE with histopathology and to determine the change in liver stiffness values after antiviral therapy. A total of 253 patients with CHB were included in this prospective study. 2D-SWE with propagation map guidance to measure liver stiffness, fibrosis-4 index (FIB-4) and aspartate aminotransferase to platelet ratio index (APRI) scoring and additional liver biopsy were performed in patients with CHB. Liver stiffness was measured again at 24 and 48 weeks in all patients. The Spearman rank correlation test was used to analyse the correlation between variables, and receiver operating curve analysis was used to evaluate the diagnostic performance in terms of fibrosis. Liver stiffness measurements made with 2D-SWE demonstrated a significant positive correlation with the fibrosis stage and FIB-4 score (r  = 0.774 and 0.337, respectively, p < 0.001 for both). The area under the curve value for kPa for the prediction of significant fibrosis was 0.956 (95% CI ) (0.920-0.991), and the optimal cut-off value was 8.2 kPa (sensitivity: 92.7% and specificity: 78.9%); these values were 0.978 (95% CI , 0.945-1.000) and 10.1 kPa (sensitivity: 92.9% and specificity: 96.4%) for the prediction of severe fibrosis. After antiviral treatment, a decrease in liver stiffness values measured by 2D-SWE was detected (mean kPa values at 0 and 48 weeks; 9.24 and 7.36, respectively, p < 0.001). In conclusion, the measurement of liver stiffness with 2D-SWE has high diagnostic performance in the determination of hepatic fibrosis and can be used to evaluate the response to treatment in patients receiving antiviral therapy.